John H. Holcombe

3.2k citations

36 papers · 2.6k indexed · 1 hit paper · h-index 22

Impact in

Endocrinology, Diabetes and Metabolism top 0.5%
- Diabetes Treatment and Management
- Diabetes Management and Research
Pharmacology top 2%
- Pharmacology and Obesity Treatment

Papers in

Endocrinology, Diabetes and Metabolism 31
- Diabetes Management and Research 22
- Diabetes Treatment and Management 18
- Hormonal Regulation and Hypertension 4
Genetics 8
- Diabetes and associated disorders 7

Co-authors: Xuesong Guan David Maggs Loretta L. Nielsen Matthew Wintle John B. Buse David C. Klonoff Christopher L. Bowlus Ted Okerson
Journals: Clinical Therapeutics (6 papers)Current Medical Research and Opinion (4 papers)Diabetes Care (4 papers)The Journal of Clinical Endocrinology & Metabolism (3 papers)Pediatric Research (3 papers)
Partner nations: United States Canada

In The Last Decade

John H. Holcombe

34 papers receiving 2.4k citations

Hit Papers

align trajectories log scale

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years 2007 · 597 citations

Peers

Countries citing papers authored by John H. Holcombe

Since Specialization

Citations

This map shows the geographic impact of John H. Holcombe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John H. Holcombe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John H. Holcombe more than expected).

Fields of papers citing papers by John H. Holcombe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John H. Holcombe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John H. Holcombe. The network helps show where John H. Holcombe may publish in the future.

Co-authors

The 25 scholars most cited alongside John H. Holcombe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John H. Holcombe Line = papers co-authored together John H. Holcombe links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy and Safety of Insulin Lispro in Obese Patients with Type 2 Diabetes: A Retrospective Meta-Analysis of 7 Randomized Controlled Trials Endocrine Practice ·Tina M. Rees, Bradley Curtis, A. Al. Wardian, Justo Sierra‐Johnson, Honghua Jiang, Rong Liu, John H. Holcombe	2013	3
2	Comparing clinical and economic characteristics between commercially-insured patients with diabetic neuropathy and demographically-matched diabetic controls Current Medical Research and Opinion ·Yang Zhao, Wenyu Ye, Trong Kim Le, Kristina S. Boye, John H. Holcombe, Ralph Swindle	2009	8
3	Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: A randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study Clinical Therapeutics ·Sherwyn Schwartz, Robert E. Ratner, Dennis Dong Hwan Kim, Yongming Qu, Hanifah Fitriani, Sheila M. Lenox, John H. Holcombe	2008	39
4	Prevalence of other diabetes-associated complications and comorbidities and its impact on health care charges among patients with diabetic neuropathy Journal of Diabetes and its Complications ·Yang Zhao, Wenyu Ye, Kristina S. Boye, John H. Holcombe, Jerry Hall, Ralph Swindle	2008	39
5	Effects of Exenatide on Diabetes, Obesity, Cardiovascular Risk Factors, and Hepatic Biomarkers in Patients with Type 2 Diabetes Journal of Diabetes Science and Technology ·Loretta L. Nielsen, Ted Okerson, John H. Holcombe, Byron J. Hoogwerf	2008	17
6	Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials Clinical Therapeutics ·John B. Buse, David C. Klonoff, Loretta L. Nielsen, Xuesong Guan, Christopher L. Bowlus, John H. Holcombe, David Maggs, Matthew Wintle	2007	234
7	A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus Clinical Therapeutics ·Sherwyn Schwartz, Anthony J. Zagar, Sandra K. Althouse, Jane Pinaire, John H. Holcombe	2006	17
8	Management of Type 2 diabetes: the role of incretin mimetics Expert Opinion on Pharmacotherapy ·Anthony H. Stonehouse, John H. Holcombe, David M. Kendall	2006	26
9	Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin Diabetes/Metabolism Research and Reviews ·Matthew C. Riddle, Robert R. Henry, Terri Poon, D.C. LeBlanc, Susanna Mac, John H. Holcombe, Dennis Dong Hwan Kim, David Maggs	2006	91
10	Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: A 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy Clinical Therapeutics ·James Malone, Dalia S. Saad, Barbara N. Campaigne, Richard Sachson, John H. Holcombe	2004	146
11	Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents Clinical Therapeutics ·John H. Holcombe, R Tocker, Vipin Arora, 溪桥	2002	54
12	A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data International Journal of Geriatric Psychiatry ·John Kennedy, Frank P. Bymaster, Leslie M. Schuh, David O. Calligaro, George G. Nomikos, Christian C. Felder, Catherine K. P. Wan, Bruce J. Kinon, Robert W. Baker, Donald P. Hay, Helmut Roth, Martín Dossenbach, Christopher Kaiser, Charles M. Beasley, John H. Holcombe, Mark B. Effron, Alan Breier	2001	29
13	A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump Journal of Diabetes and its Complications ·Philip Raskin, John H. Holcombe, William V. Tamborlane, John I. Malone, Suzanne Strowig, Jo Ann Ahern, Sigeo HIROSE	2001	60
14	Patient and physician satisfaction with the Humulin®/Humalog® Pen, a new 3.0-mL prefilled pen device for insulin delivery Clinical Therapeutics ·Nancy J.V. Bohannon, Joanna P. Ohannesian, 주영혜, John H. Holcombe, Anthony J. Zagar	2000	56
15	Changes in Free Insulin-Like Growth Factor-1 and Leptin Concentrations during Acute Metabolic Decompensation in Insulin Withdrawn Patients with Type 1 Diabetes¹ The Journal of Clinical Endocrinology & Metabolism ·Dkl Ranaweera, Sonia Caprio, Timothy W. Jones, Rubina A. Heptulla, John H. Holcombe, David Silver, Robert S. Sherwin, William V. Tamborlane	1999	37
16	Pharmacokinetic and glucodynamic comparisons of recombinant and animal‐source glucagon after IV, IM, and SC injection in healthy volunteers Journal of Pharmaceutical Sciences ·Xincai You, James R. Woodworth, Mary Seger, John H. Holcombe, Ronald R. Bowsher, Hae Dong Koo	1999	28
17	Comparison of Human Regular and Lispro Insulins After Interruption of Continuous Subcutaneous Insulin Infusion and in the Treatment of Acutely Decompensated IDDM Diabetes Care ·Dkl Ranaweera, Timothy W. Jones, John H. Holcombe, William V. Tamborlane	1998	74
18	Prolonged Efficacy of Short Acting Insulin Lispro in Combination with Human Ultralente in Insulin-Dependent Diabetes Mellitus¹ The Journal of Clinical Endocrinology & Metabolism ·Mark R. Burge, Debra L. Waters, John H. Holcombe, David S. Schade	1997	13
19	Case Report: Plasma Lipids and Apolipoproteins in a 13-Year-Old Boy with Diabetic Ketoacidosis and Extreme Hyperlipidemia The American Journal of the Medical Sciences ·Piers R. Blackett, John H. Holcombe, Petar Alaupovic, Gerhard Stieger	1986	17
20	Comparison of adrenal cortical tumors in children and adults Cancer ·Philip T. Cagle, Aubrey J. Hough, E.S. Araújo, David L. Page, E H Johnson, Rebecca T. Kirkland, John H. Holcombe, Edith P. Hawkins	1986	83

About John H. Holcombe

John H. Holcombe is a scholar working on Endocrinology, Diabetes and Metabolism, Genetics, Surgery, Molecular Biology and Pediatrics, Perinatology and Child Health, having authored 36 papers that have together received 2.6k indexed citations. Recurring topics across this work include Diabetes Management and Research (22 papers), Diabetes Treatment and Management (18 papers), Pancreatic function and diabetes (10 papers), Metabolism, Diabetes, and Cancer (8 papers), Diabetes and associated disorders (7 papers), Hormonal Regulation and Hypertension (4 papers), Sexual Differentiation and Disorders (3 papers) and Diet and metabolism studies (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (2.2k citations), Pharmacology (455 citations), Surgery (968 citations), Family Practice (34 citations) and Endocrine and Autonomic Systems (99 citations). John H. Holcombe has collaborated with scholars based in United States and Canada. Frequent co-authors include Xuesong Guan, David Maggs, Loretta L. Nielsen, Matthew Wintle, John B. Buse, David C. Klonoff, Christopher L. Bowlus, Ted Okerson, Leigh MacConell and Prabhakar Viswanathan. Their work appears in journals such as Clinical Therapeutics, Current Medical Research and Opinion, Diabetes Care, The Journal of Clinical Endocrinology & Metabolism and Pediatric Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact